Mirvie RNA test aims to predict pregnancy complications

A recent study identified distinct gene signatures in placentae from gestational diabetes and pregestational diabetes pregnancies, offering potential for improved diagnosis and treatment strategies.

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

A recent study suggests that the soluble fms-like tyrosine kinase 1 to placental growth factor ratio can help predict clinical deterioration, intrapartum fetal distress, and mode of delivery, offering valuable insights for patient counseling and labor management.

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

A recent study reveals significantly lower initiation and continuation rates of Mother’s own milk feeding among late preterm infants compared to other gestational age groups, highlighting a need for targeted support.

A recent study found that women with a history of gestational diabetes who sleep less or snore regularly face a significantly higher risk of developing type 2 diabetes later in life.